Abstract
Infiltrating inflammatory cells into the kidney mediate the initiation and progression of damage by direct cytotoxicity, the secretion of soluble factors such as cytokines and proteases, or by the subsequent induction of further immune response. Before leukocytes can exert their effects on renal damage or repair, they have to reach the site of injury. It has become clear in recent years that a group of small proteins called chemokines are the chemotactic cytokines considered to be the main regulators of directional leukocyte trafficking under homeostatic and inflammatory conditions. In this review, we summarize available in vivo studies on the neutralization of chemokines and chemokine receptors in renal inflammatory disease, and especially focus on the potential therapeutic effects of chemokine blockade in glomerulonephritis and renal transplantation. Although interference with chemokine expression holds great promises for the treatment of inflammatory renal diseases, it has been shown that such an approach may actually worsen in diseases under certain circumstances. This suggests that inhibition of chemokine expression and action must be time and compartment specific to provide therapeutic benefit for renal structure and function.
Keywords: Chemokine receptor, glomerulonephritis, renal transplantation, inflammation
Current Drug Targets
Title: Kidney Diseases and Chemokines
Volume: 7 Issue: 1
Author(s): Ulf Panzer, Oliver M. Steinmetz, Rolf A.K. Stahl and Gunter Wolf
Affiliation:
Keywords: Chemokine receptor, glomerulonephritis, renal transplantation, inflammation
Abstract: Infiltrating inflammatory cells into the kidney mediate the initiation and progression of damage by direct cytotoxicity, the secretion of soluble factors such as cytokines and proteases, or by the subsequent induction of further immune response. Before leukocytes can exert their effects on renal damage or repair, they have to reach the site of injury. It has become clear in recent years that a group of small proteins called chemokines are the chemotactic cytokines considered to be the main regulators of directional leukocyte trafficking under homeostatic and inflammatory conditions. In this review, we summarize available in vivo studies on the neutralization of chemokines and chemokine receptors in renal inflammatory disease, and especially focus on the potential therapeutic effects of chemokine blockade in glomerulonephritis and renal transplantation. Although interference with chemokine expression holds great promises for the treatment of inflammatory renal diseases, it has been shown that such an approach may actually worsen in diseases under certain circumstances. This suggests that inhibition of chemokine expression and action must be time and compartment specific to provide therapeutic benefit for renal structure and function.
Export Options
About this article
Cite this article as:
Panzer Ulf, Steinmetz M. Oliver, Stahl A.K. Rolf and Wolf Gunter, Kidney Diseases and Chemokines, Current Drug Targets 2006; 7 (1) . https://dx.doi.org/10.2174/138945006775270213
DOI https://dx.doi.org/10.2174/138945006775270213 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
Current Alzheimer Research Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis
Current Medicinal Chemistry Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Pharmacogenetics and Statin Treatment: Reality or Theory?
Current Vascular Pharmacology Novel Therapeutic Targets for Somatostatin in Inflammatory Chronic Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Common and Uncommon Features of Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease: Clues to a Future Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Prospective of Natural Gum Nanoparticulate Against Cardiovascular Disorders
Current Chemical Biology ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets Pulmonary Hemorrhage in Patients with Systemic Lupus Erythematosus
Current Respiratory Medicine Reviews Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Emerging Targets in Neurodegeneration: New Opportunities for Alzheimer's Disease Treatment?
Current Topics in Medicinal Chemistry Alterations in the Vascular Reactivity of Aorta in the Early and Late Phase of Adjuvant-Induced Arthritis in Rat
Vascular Disease Prevention (Discontinued) A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index
Current Drug Targets - Inflammation & Allergy The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry